Intensive Care Medicine

, Volume 36, Issue 7, pp 1278–1279 | Cite as

Esomeprazole-induced rhabdomyolysis in a patient with heart failure

  • Uwe TrögerEmail author
  • Ines Reiche
  • Marilene S. Jepsen
  • Christof Huth
  • Stefanie M. Bode-Böger

A 75-year-old male patient with chronic heart failure underwent aortic valve replacement and coronary artery bypass surgery and was transferred to our intensive care unit. He also suffered from renal failure and diabetes mellitus. He was sedated initially by propofol and sufentanil for mechanical ventilation. Other medications were insulin, heparin (800 IU/h), furosemide (40–120 mg/day), amiodarone (36 mg/h), meropenem (2 g/day), linezolid (1,200 mg/day) and catecholamines. Intravenous esomeprazole was administered (40–80 mg/day) for stress ulcer prophylaxis. Furthermore, the patient was treated with continuous veno-venous haemofiltration for 12 days.

After the successful surgery procedure, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) and the C-reactive protein (CRP) levels decreased, but myoglobin remained elevated. After excluding several clinical reasons, the most probable drugs known to cause rhabdomyolysis—propofol and amiodaron—were discontinued....


Proton Pump Inhibitor Linezolid Sufentanil Esomeprazole Stress Ulcer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest statement

We certify that there is no actual or potential conflict of interest in relation to this article.


  1. 1.
    Huerta-Alardin AL, Varon J, Marik PE (2005) Bench-to-bedside review: rhabdomyolysis—an overview for clinicians. Crit Care 9:158–169CrossRefPubMedGoogle Scholar
  2. 2.
    Mikkelsen TS, Toft P (2005) Prognostic value, kinetics and effect of CVVHDF on serum of the myoglobin and creatine kinase in critically ill patients with rhabdomyolysis. Acta Anaesthesiol Scand 49:859–864CrossRefPubMedGoogle Scholar
  3. 3.
    Quenot JP, Thiery N, Barbar S (2009) When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care 15:139–143CrossRefPubMedGoogle Scholar
  4. 4.
    Clark DWJ, Strandell J (2006) Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol 62:473–479CrossRefPubMedGoogle Scholar
  5. 5.
    Wilder-Smith CH, Bondarov P, Lundgren M, Niazi M, Röhss K, Ahlbom H, Nyman L (2005) Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies. Eur J Gastroenterol Hepatol 17:191–197CrossRefPubMedGoogle Scholar
  6. 6.
    Sivakumar K, Dalakas MC (1994) Autoimmune syndrome induced by omeprazole. Lancet 344:619–620CrossRefPubMedGoogle Scholar
  7. 7.
    Schönhöfer PS, Werner B, Tröger U (1997) Ocular damage associated with proton pump inhibitors. Br Med J 314:1805Google Scholar

Copyright information

© Copyright jointly held by Springer and ESICM 2010

Authors and Affiliations

  • Uwe Tröger
    • 1
    Email author
  • Ines Reiche
    • 1
  • Marilene S. Jepsen
    • 2
  • Christof Huth
    • 2
  • Stefanie M. Bode-Böger
    • 1
  1. 1.Institute of Clinical PharmacologyOtto-von-Guericke-University MagdeburgMagdeburgGermany
  2. 2.Clinic for Heart and Thoracic SurgeryOtto-von-Guericke-University MagdeburgMagdeburgGermany

Personalised recommendations